About: Cluster of COVID-19 in northern France: A retrospective closed cohort study

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Cluster of COVID-19 in northern France: A retrospective closed cohort study Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Cluster of COVID-19 in northern France: A retrospective closed cohort study
Creator	Fontanet, Arnaud Temmam, Sarah Cauchemez, Simon Eloit, Marc Schwartz, Olivier Gallian, Pierre Grant, Rebecca Hoen, Bruno Besombes, Camille Cailleau, Isabelle Chen, Kuang-Yu Fernandes, Sandrine Huon, Christèle Jolly, Nathalie Kuhmel, Lucie Madec, Yoann Tondeur, Laura Ungeheuer, Marie-Noëlle
Source	MedRxiv
abstract	Background: The Oise department in France has been heavily affected by COVID-19 in early 2020. Methods: Between 30 March and 4 April 2020, we conducted a retrospective closed cohort study among pupils, their parents and siblings, as well as teachers and non-teaching staff of a high-school located in Oise. Participants completed a questionnaire that covered history of fever and/or respiratory symptoms since 13 January 2020 and had blood tested for the presence of anti-SARS-CoV-2 antibodies. The infection attack rate (IAR) was defined as the proportion of participants with confirmed SARS-CoV-2 infection based on antibody detection. Blood samples from two blood donor centres collected between 23 and 27 March 2020 in the Oise department were also tested for presence of anti-SARS-CoV-2 antibodies. Findings: Of the 661 participants (median age: 37 years), 171 participants had anti-SARS-CoV-2 antibodies. The overall IAR was 25.9% (95% confidence interval (CI) = 22.6-29.4), and the infection fatality rate was 0% (one-sided 97.5% CI = 0-2.1). Nine of the ten participants hospitalised since mid-January were in the infected group, giving a hospitalisation rate of 5.3% (95% CI = 2.4-9.8). Anosmia and ageusia had high positive predictive values for SARS-CoV-2 infection (84.7% and 88.1%, respectively). Smokers had a lower IAR compared to non-smokers (7.2% versus 28.0%, P <0.001). The proportion of infected individuals who had no symptoms during the study period was 17.0% (95% CI = 11.2-23.4). The proportion of donors with anti-SARS-CoV-2 antibodies in two nearby blood banks of the Oise department was 3.0% (95% CI = 1.1-6.4). Interpretation: The relatively low IAR observed in an area where SARS-CoV-2 actively circulated weeks before confinement measures indicates that establishing herd immunity will take time, and that lifting these measures in France will be long and complex.
has issue date	2020-04-23(xsd:dateTime)
bibo:doi	10.1101/2020.04.18.20071134
has license	medrxiv
sha1sum (hex)	55134bb8ff89ac7a3c730f4dc1f5a9ed144a817e
schema:url	https://doi.org/10.1101/2020.04.18.20071134
resource representing a document's title	Cluster of COVID-19 in northern France: A retrospective closed cohort study
resource representing a document's body	covid:55134bb8ff89ac7a3c730f4dc1f5a9ed144a817e#body_text
is schema:about of	named entity 'infection' named entity 'fever' named entity 'covered' named entity 'IAR' named entity 'CONFIRMED' named entity 'BLOOD' named entity 'BLOOD DONOR' named entity 'Oise' named entity 'defined' named entity 'Participants' named entity 'blood' named entity 'retrospective' named entity 'infection' named entity 'antibody' named entity 'blood donor' named entity 'Oise' named entity 'Oise' named entity 'SARS-CoV-2' named entity 'antibodies' named entity 'SARS-CoV-2' named entity 'infection' named entity 'medRxiv' named entity 'China' named entity 'blood donor' named entity 'preprint' named entity 'age-standardised' named entity 'preprint' named entity 'widely reported' named entity 'case fatality rate' named entity 'medRxiv' named entity 'infection' named entity 'COVID-19' named entity 'serologic' named entity 'serological test' named entity 'etiology' named entity 'COVID' named entity 'IgG' named entity 'smokers' named entity 'medRxiv' named entity 'Blood donors' named entity 'Informed consent' named entity 'preprint' named entity 'preprint' named entity 'preprint' named entity 'epidemics' named entity 'ageusia' named entity 'Wuhan' named entity 'chi-squared test' named entity 'antibody' named entity 'smokers' named entity 'preprint' named entity 'subclinical' named entity 'infection' named entity 'infection' named entity 'Shenzen' named entity 'anosmia' named entity 'blood sample' named entity 'vaccines' named entity 'SARS-CoV-2' named entity 'antibodies' named entity 'medRxiv' named entity 'RT-PCR' named entity 'COVID' named entity 'seroconversion' named entity 'SARS-CoV-2' named entity 'serological assay' named entity 'preprint' named entity 'viruses'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software